BI 1815368 clinical trials
Also written BI 1815368.
How each study uses BI 1815368 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the BI 1815368 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BI 1815368
- 5
Studies by the year they started
7 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses BI 1815368 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular EdemaRecruitingPhase 2Boehringer IngelheimNCT06962839Written as BI 1815368
- A Study in Healthy Men to Test How BI 1815368 is Processed in the BodyCompletedPhase 1Boehringer IngelheimNCT07693218Written as BI 1815368 (C-14)
- A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1815368 in the BloodCompletedPhase 1Boehringer IngelheimNCT05965583Written as BI 1815368
- A Study in Healthy Men to Test Whether BI 1815368 Influences the Amount of Metformin in the BodyCompletedPhase 1Boehringer IngelheimNCT06655220Written as BI 1815368
- A Study to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body of Healthy Japanese MenCompletedPhase 1Boehringer IngelheimNCT06494774Written as BI 1815368
- A Study to Test How Well Different Doses of BI 1815368 Are Tolerated by Healthy MenCompletedPhase 1Boehringer IngelheimNCT05857878Written as BI 1815368
- A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without FoodCompletedPhase 1Boehringer IngelheimNCT05337592Written as BI 1815368 formulation 1